Rapid diagnosis and early antibiotic therapy for Group A Streptococcal infection are the best means of preventing medical complications and reducing the spread of the disease¹.
BD Veritor™ System for Rapid Detection Videos:
BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2
Learn about the BD Veritor System for the Rapid Detection of SARS-CoV-2 with the BD Veritor Plus Analyzer. The BD portable Veritor Plus Portable Analyzer is a point-of-care system used to test for flu or strep. Now that same system can be used for the detection of SARS-CoV-2 Covid-19 antigens, providing results in 15 minutes.
Performing COVID-19 Testing
Watch the video to your right to learn how to perform rapid Covid-19 (SARS-CoV-2) testing with the BD Veritor™ Plus System.
COVID-19 and Flu A+B Testing
This video helps you learn about rapid COVID-19 and Flu A+B testing with the BD Veritor™ Plus System.
BD Veritor™ Plus System - Keys to Successful Testing
This video explains that following a set of best practices when using your BD Veritor™ Plus System is critical to ensure the highest degree of accuracy possible
BD Veritor Plus Analyzer System Instructional Videos
* The intended use of the BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 assay only includes those who are suspected of COVID-19 by their health care providers within the first five days on the onset of symptoms.
This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories
This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and
This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.